Provencio, M., Terrasa, J., Garrido, P., Campelo, R. G., Aparisi, F., Diz, P., . . . Calvo de Juan, V. (2021). Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Citación estilo ChicagoProvencio, Mariano, et al. Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. 2021.
Cita MLAProvencio, Mariano, et al. Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. 2021.